Form 4: Corcept CDO Sells 20,000 Shares After Option Exercise

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options for 20,000 shares and subsequently sold all of them for approximately $1.5 million.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), executed transactions on November 5, 2025.
• Guyer exercised stock options to acquire 20,000 shares of common stock at an exercise price of $21.65 per share.
• Concurrently, Guyer sold all 20,000 shares acquired through the option exercise.
• The sales occurred at weighted average prices of $74.7489 (6,536 shares), $75.6365 (13,164 shares), and a direct price of $76.28 (300 shares).
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2024.
• Following these transactions, Guyer directly owns 5,287 shares of common stock and 290,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it was pre-planned under a 10b5-1 plan, which mitigates negative interpretations. The significant gain realized by the officer also reflects positively on the company's stock performance.

Positives

• The officer realized a significant gain from the option exercise and sale, indicating a substantial increase in the company's stock price since the options were granted (exercise price $21.65 vs. sale prices ~$75).
• The transactions were pre-planned under a Rule 10b5-1 plan, suggesting the sales were not based on new, non-public information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the officer's direct equity stake.

Future Outlook

NA

Industry Context

This is a routine insider transaction (Form 4) for a biopharmaceutical company. Such transactions are common for executives managing their equity compensation and personal finances, especially when executed under a pre-arranged 10b5-1 plan. It does not inherently reflect on the company's operational performance or broader industry trends, though the high sale price relative to the exercise price indicates strong stock performance.

Stakeholder Impact

• Shareholders: The sale by a Chief Development Officer, even if pre-planned, could be viewed with slight caution, but the 10b5-1 plan mitigates concerns about opportunistic selling. The significant profit realized by the officer highlights the value creation for all shareholders who held the stock over the option's vesting period.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction (exercise of options and subsequent sale of shares) by a Chief Development Officer. While it represents a reduction in the officer's direct equity holdings, the execution under a Rule 10b5-1 plan suggests it's for personal financial management rather than a signal about the company's future prospects. The substantial profit realized by the officer from the option exercise reflects positively on the company's past stock performance. Without additional information on the company's fundamentals or future outlook, this specific Form 4 filing alone does not warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Option Exercise, Share Sale, William Guyer, Chief Development Officer, Rule 10b5-1